The US Food and Drug Administration (FDA) is stepping up its oversight on Chinese manufacturers of pharmaceutical ingredients to improve the safety of the US drug supply chain, the South China Morning Post cited the agency’s China office director, Christopher Hickey, as saying Thursday. “As the number of medical products coming from China has increased, so have the challenges,” Hickey was quoted as saying. Armed with new legal authority and additional funding, the FDA has begun adding staff and inspectors in China, he said. Hickey was one of several witnesses who testified before a hearing of the US-China Economic and Security Review Commission, the paper noted.
– Contact HKEJ at [email protected]